40results about How to "Delay progress" patented technology

The invention discloses a senile weakness and Parkinson's disease multi-dimensional evaluation system based on an intelligent single-chip microcomputer, and belongs to the technical field of disease evaluation. The senile weakness and Parkinson's disease multi-dimensional evaluation system comprises a data acquisition module used for acquiring patient multi-dimensional real-time data based on artificial intelligence; the data transmission module is used for uploading the multi-dimensional real-time data of the patient based on artificial intelligence to the multi-dimensional evaluation terminal; and the multi-dimensional evaluation terminal is used for processing, analyzing and evaluating the multi-dimensional real-time data of the patient based on artificial intelligence, and determining a multi-dimensional evaluation result of senile weakness and Parkinson's disease based on the intelligent single-chip microcomputer. The problems that real-time monitoring and multi-dimensional evaluation cannot be carried out on senile weakness and Parkinson's disease based on an intelligent single-chip microcomputer in the prior art, and disease deterioration cannot be effectively prevented are solved. Real-time monitoring and multi-dimensional evaluation can be performed on senile weakness and Parkinson's disease on the basis of the intelligent single chip microcomputer, the illness state of a patient can be mastered in time, the patient can be tracked and treated in time, disease progression is slowed down, and deterioration of the illness state can be effectively prevented.

The invention discloses a Parkinson's disease early diagnosis system based on eyeball movement characteristic analysis, and relates to the technical field of Parkinson's disease diagnosis. In order to solve the problems that although eye and face movement parameters possibly change in Parkinson's disease, the change of the parameters also possibly occurs in other neurodegenerative diseases or normal aging processes, and high-precision eye and face movement capture data is complex, so that early diagnosis characteristics of Parkinson's disease cannot be accurately captured, and the Parkinson's disease cannot be accurately diagnosed. And the accuracy and efficiency of diagnosis are influenced. By accurately capturing and analyzing eyeball movement data and facial expression video images of a patient, the Parkinson's disease can be effectively distinguished from other diseases possibly causing similar symptoms, misdiagnosis and missed diagnosis are reduced, the standardization and comparability of data are ensured by combining pupil distance information and diopter information, the consistency and reliability of diagnosis are improved, and the diagnosis accuracy is improved. Therefore, the patient can be diagnosed at the early stage of the disease and is treated as soon as possible, and the treatment effect and life quality are improved.

The present invention discloses a CD33 blocking antibody, which is HZAB_1 or HZAB_2; the amino acid sequence of the heavy chain variable region of HZAB_1 is shown in SEQ ID NO.1; the amino acid sequence of the light chain variable region of HZAB_1 is shown in SEQ ID NO.2; the amino acid sequence of the heavy chain variable region of HZAB_2 is shown in SEQ ID NO.3; the amino acid sequence of the light chain variable region of HZAB_2 is shown in SEQ ID NO.4. HZAB_1 and HZAB_2 antibodies can improve the phagocytic efficiency of macrophages on colorectal neuroendocrine cancer cells and small cell lung cancer cells, and slow down the progression of colorectal neuroendocrine cancer and small cell lung cancer.

The invention provides a monoclonal antibody 6G2 resisting DENV NS1 protein and application of the monoclonal antibody 6G2. The CDR amino acid sequence of a heavy chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.1, and the CDR amino acid sequence of a light chain of the monoclonal antibody 6G2 resisting the DENV NS1 protein is shown as SEQ ID No.3. The invention also provides application of the monoclonal antibody 6G2 to preparation of drugs for treating dengue virus infection, and the monoclonal antibody 6G2 for resisting DENV NS1 protein has the performances of competitively binding DENV1-4NS1 protein, inhibiting vascular leakage symptoms and protecting DENV infected fatal injury in vivo, and has potential important value for treating severe dengue fever. The monoclonal antibody 6G2 developed by the invention has important significance and application potential for prevention and treatment of dengue virus infection, including severe dengue fever.

The invention discloses an intelligent lavage and drainage system for gastrointestinal surgery in the technical field of gastrointestinal surgery, and the system comprises an information collection module which is used for collecting gastrointestinal pressure information of a patient and recording and storing the pressure information; the data analysis and processing module is used for establishing a pressure model and a pressure threshold value by utilizing a machine learning algorithm based on the collected pressure information; the intelligent control module is used for controlling the flow speed and flow of the lavage fluid and the drainage fluid in different time periods according to the pressure information; and the early warning module is used for monitoring abnormal conditions of the gastrointestinal tract, automatically starting a drainage function and sending out an alarm signal when monitoring that the pressure information exceeds a preset pressure threshold value. By analyzing the relevance between various characteristic information and gastrointestinal tract environment information of the patient, the lavage and drainage parameters are automatically adjusted according to individual differences of the patient, and a more personalized treatment scheme can be provided, so that the treatment effect is improved.

The present invention relates to the use of pharmaceutical compositions comprising nicotinamide (NAM) and / or pyruvic acid as neuroprotective drugs or gene therapy in the treatment of axonal degeneration of neuronal tissue in neurodegenerative disorders, particularly eye-related neurodegenerative diseases, including glaucoma.

The invention relates to the technical field of biology, in particular to a matrix-enabled mesenchymal stem cell aggregate and application, and the matrix-enabled mesenchymal stem cell aggregate is obtained by subculturing matrix-enabled mesenchymal stem cells in a 3D cell culture system. The matrix-enabled mesenchymal stem cells are obtained by subculture of mesenchymal stem cells in a cell culture matrix, and the cell culture matrix is prepared from 1-3 parts of hE-cad-Fc and 1-3 parts of hN-cad-Fc. Endogenous epithelium cadherin and nerve cadherin are highly expressed in cell aggregation cells, so that transcription factors are promoted to enter nuclei, the expression levels of anti-inflammatory immune regulation related factors and matrix degradation and cell migration related factors are up-regulated, and activated macrophages are promoted to be polarized to M2 type macrophages; the effects of anti-inflammation, immune regulation, tissue damage repair and the like of intravenous implantation of the matrix-enabled mesenchymal stem cell aggregate for treating diseases such as hepatic fibrosis, diabetes mellitus, nerve injury and the like are remarkably improved.

The invention discloses a pirfenidone solution for inhalation and a use method thereof, and belongs to the technical field of pulmonary fibrosis, the pirfenidone solution is prepared from the following raw materials in parts by weight: pirfenidone and an isotonic agent in a mass ratio of (10-50): 28, during preparation, a dissolving agent accounting for 80% of the dosage of the pirfenidone and the isotonic agent is measured, the solution temperature is controlled to be 40 DEG C, the solution preparation time is 60 min, the volume is fixed to 4 mL, and the solution is prepared into the solution. And filtering the solution through a polyether filter membrane, and filling into an ampoule bottle. The invention relates to a pirfenidone solution for inhalation and a use method thereof, and solves the technical problem that in the prior art, the gastrointestinal tract effect and hepatotoxicity of pirfenidone are obvious when the pirfenidone is orally taken.

This invention discloses the application of a reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis, belonging to the field of biomedical technology. The application of the reagent that inhibits ADNP gene expression or ADNP protein activity in the preparation of drugs for treating renal fibrosis. This invention effectively knocks down or knocks out the ADNP gene in renal tubular epithelial cells, objectively investigates the effects of ADNP deficiency on a series of phenotypes in HK-2 cells, and confirms that ADNP can inhibit EMT and renal fibrosis in HK-2 cells. Drugs that target and knock down or knock out the ADNP gene in human kidneys can be developed to delay the progression of renal fibrosis.

The application relates to the field of biological medicine, and provides application of hydrochloric acid dinedarong in preparation of a medicine for treating non-alcoholic fatty liver disease and cholestatic liver disease. The application discloses a new medical use of hydrochloric acid dinedarong, which can significantly reduce liver injury, lipid deposition in the liver and liver fibrosis caused by high-fat high-fructose high-cholesterol diet, and can reduce liver injury and liver fibrosis caused by cholestasis. Therefore, the hydrochloric acid dinedarong has the effect of treating non-alcoholic fatty liver disease and cholestatic liver disease.

This invention relates to the field of medical data processing technology, and discloses an Alzheimer's disease prediction method, system, device, and medium, comprising: obtaining spectral data of a target group in a non-invasive manner; training an Alzheimer's disease prediction model based on the spectral data; the target group includes healthy individuals and individuals with Alzheimer's disease. This invention non-invasively obtains samples from the target group, utilizing the advantages of laser-induced breakdown spectroscopy (LAS) for simultaneous detection and analysis of all elements at high speed. It achieves qualitative or quantitative analysis of the chemical composition of material surfaces by measuring the emission spectrum of micro-plasma, accurately and rapidly obtaining spectral data of the target group. The Alzheimer's disease prediction model trained based on the spectral data can effectively assist doctors in early screening of individuals, enabling early intervention for patients with early-stage Alzheimer's disease, and has broad application prospects.

An application of a mitoxantrone preparation in preparation of a drug for diagnosing and treating a disease related to thyroidectomy, and use of mitoxantrone and / or a pharmaceutically acceptable salt thereof in preparation of a lymph tracer for preventing parathyroid gland staining in error, preventing parathyroid gland cutting in error, or reducing the rate of parathyroid gland cutting in error. Local injection of a mitoxantrone hydrochloride injection fluid would not cause parathyroid gland staining in error, and can reduce the rate of parathyroid gland cutting in error, thus protecting parathyroid glands well; moreover, no local or systemic toxic side effect is found after the local injection. The present invention has good tolerability, efficacy, and safety, and provides a new treatment idea in radically curing thyroid diseases thoroughly for patients suffering from diseases related to thyroidectomy.

The invention relates to a traditional Chinese medicine composition for preventing and treating ocular surface injury caused by xerophthalmia and application thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 20-40 parts of spica prunellae, 20-40 parts of radix astragali, 5-25 parts of rhizoma polygonati, 5-25 parts of folium mori and 5-25 parts of fructus crataegi. Compared with the prior art, the traditional Chinese medicine composition disclosed by the invention consists of five medicinal and edible Chinese herbal medicines, is simple and convenient to take, safe and free from side effects, and can be popularized and used as a medicine for preventing and treating xerophthalmia. The traditional Chinese medicine composition disclosed by the invention can be used for remarkably inhibiting the corneal injury related to the xerophthalmia, maintaining the number of conjunctival goblet cells and providing new treatment for relieving the ocular surface injury of the xerophthalmia.

The invention relates to the technical field of neurology, in particular to a composition for treating brain injury and neurodegenerative lesion and application thereof, the composition is composed of an antioxidant and an anti-inflammatory drug, the antioxidant comprises vitamins, flavonoids, polysaccharides, saponins and active peptides according to the mass ratio of 4: 3: 1: 4: 2, and the content of the antioxidant is 60-80 parts; the anti-inflammatory drug comprises a non-steroidal anti-inflammatory drug NSAIDs, and the number of the components of the anti-inflammatory drug is 20-40 parts. By utilizing the synergistic effect of various active ingredients, the traditional Chinese medicine composition can comprehensively improve the symptoms of a patient, relieve pain, improve sleep and improve the cognitive function, thereby delaying neurodegenerative diseases and being beneficial to improving the functional state of neurons.

The present invention provides a use of NLN neurolysin in preparing a drug for preventing and treating lung cancer, and the present invention belongs to the field of medical science. It is first found that the level of NLN neurolysin in lung cancer tissue of lung cancer patients is significantly higher than that in adjacent cancer tissue. The present invention verifies that knocking out the NLN neurolysin gene can effectively prevent and treat lung cancer through gene knockout, and the present invention provides a target and treatment strategy for clinical treatment of lung cancer.

The invention discloses a novel Tau proteopathy treatment target PRMT3, and relates to the technical field of Tau proteopathy treatment, the key points of the technical scheme are as follows: the target PRMT3 is used for promoting asymmetric dimethylation of histone H4R3, and the action flow of the target PRMT3 is as follows: methylated H4R3me2a is combined with a promoter region of miR-448 to promote transcription of miR-448, so that the target PRMT3 is obtained. Meanwhile, excessive miR-448 is combined with mRNA of IGF1R through complementary base pairing, so that the mRNA of the IGF1R is degraded, a PI3K / AKT / GSK3beta signal axis is further inhibited, and the phosphorylation level of Tau is promoted. According to the application, PRMT3 is taken as a therapeutic target, Tau pathological changes can be effectively relieved by knocking down the expression level of PRMT3 or using an inhibitor to reduce the activity of PRMT3 protein, and the neuronal function and the cognitive function are improved.

The invention relates to an application of breast milk oligosaccharide in preparation of a preparation for inhibiting proliferation of intestinal tract Ruminococcus, the breast milk oligosaccharide is 2 '-FL and / or 6'-SL, the relative abundance of the intestinal tract Ruminococcus can be obviously reduced, the proliferation of the intestinal tract Ruminococcus can be inhibited, and the breast milk oligosaccharide can be applied to preparation of the preparation for inhibiting the proliferation of the intestinal tract Ruminococcus. The breast milk oligosaccharide is 2 '-FL or a composition of 2'-FL and 6 '-SL, compared with 2'-FL or a composition of 2 '-FL and 6'-SL, the breast milk oligosaccharide has a better inhibition effect on intestinal tract Ruminococcus, can be applied to preparation of a preparation for inhibiting abnormal proliferation of intestinal tract Ruminococcus of a patient suffering from the inflammatory bowel disease, and is particularly applied to preparation of a preparation for preventing enteritis and maintaining intestinal health.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an MYC mRNA translation inhibitor in preparation of a medicine for preventing and / or treating osteoarthritis. The MYC mRNA translation inhibitor is selected from biological materials capable of inhibiting or blocking the MYC mRNA translation process, reducing the MYC protein synthesis efficiency or interfering the MYC mRNA steady state level. The invention provides a novel molecular target capable of being used for treating osteoarthritis and a medicine application scheme of the molecular target.

The present application relates to the technical field of medicine, especially relates to application of a small molecule compound LZ-09 in preparation of a medicine for treating and / or preventing multiple sclerosis. The present application adopts H2O2 damage OLN-93 cells as a nerve cell oxidative stress model, and the result shows that LZ-09 treatment significantly weakens the cell viability decrease caused by H2O2. The classic EAE model is made by using MOG35-55 to induce C57BL / 6 mice, and it is found that after LZ-09 intervention, the mouse neurological deficit symptom score is significantly reduced, and the disease progression is delayed, and spinal cord tissue HE and LFB staining find that the inflammation infiltration and demyelination are reduced. Therefore, the compound can effectively alleviate the symptoms of multiple sclerosis, can be used as a medicine for treating multiple sclerosis, and has wide development and application prospect.

The utility model relates to rare earth hydrogen storage alloy or quick -setting neodymium iron boron alloy smelting auxiliary equipment technical field, specific, relate to a kind of rare earth metal powder explosion -proof dust collecting device, including shell, filter bag chamber, backflush mechanism, dust-containing gas inlet, purified gas outlet, still include inert gas supply gas path, explosion suppressor, explosion vent. Nitrogen gas path is introduced on the one hand reduces the oxygen content in dust collecting device, makes oxygen concentration reduce, reduces the oxidation reaction of rare earth metal, reduces the generation of heat. On the other hand, nitrogen in nitrogen gas path low pressure gas path is obtained by high-pressure liquid nitrogen throttling pressure reduction, temperature is lower, it is favorable to reduce the temperature in dust collecting device. The introduction of nitrogen gas path greatly reduces the explosion risk, this is the conventional working process. By introducing explosion suppressor, explosion vent, cooling can be carried out when temperature is too high and pressure relief after explosion, to slow down the progress of explosion and protect the entire device after explosion.

The invention aims to provide a traditional Chinese medicine composition for treating AIDS (Acquired Immune Deficiency Syndrome). The pharmaceutical composition is prepared by processing the following raw material medicines: astragalus membranaceus, codonopsis pilosula, radix scrophulariae, bran-fried rhizoma atractylodis macrocephalae, Chinese yam, pericarpium citri reticulatae, angelica sinensis, salvia miltiorrhiza, ligusticum wallichii, radix cyathulae, raw liquorice, scorched hawthorn fruit, scorched medicated leaven and scorched malt. Pharmacodynamic tests prove that the medicine can enhance the immune function of AIDS patients, delay the decline speed of CD4 + T cells, activate latent HIV viruses and reservoirs, slow down the disease progress, protect the liver function, relieve clinical symptoms and the like.

This invention belongs to the field of pharmaceutical preparation technology, specifically relating to a hyaluronic acid-modified co-supported nanoparticle, its preparation method, and its application. The nanoparticle has a core-shell structure, with the core being a coordination complex of zinc-doped Prussian blue and sinomenine hydrochloride, and the outer shell being a bovine serum albumin-hyaluronic acid conjugate. This invention improves the therapeutic effect on knee osteoarthritis.

The invention discloses a fusion polypeptide RAT-1 and application thereof in hypertension treatment. The topological structure of the fusion polypeptide is a kidney targeting head-ACE2 functional segment-MMP responsive connexon-AT1 receptor antagonism segment, and the full-length sequence is as shown in SEQ ID No: 1. The kidney targeting head can be specifically combined with megalin receptors of renal tubular epithelial cells to realize kidney targeting delivery; the ACE2 functional segment can efficiently degrade angiotensin II; the MMP responsive connexon is specifically cut in a focus microenvironment, and an AT1 receptor antagonism segment is released; the AT1 receptor antagonist segment can block the receptor signal channel of angiotensin II. The fusion polypeptide has good plasma stability, shows a powerful and long-acting antihypertensive effect in a spontaneous hypertension rat model, is remarkable in kidney targeting, and can relieve renal fibrosis and protect podocyte functions. The fusion polypeptide disclosed by the invention realizes a synergistic effect of targeted delivery, enzymolysis catalysis, response release and receptor antagonism, and can be used for preparing hypertension treatment medicines and kidney protection medicines.

The application provides a preparation method of a compound SS-23 and an application of the compound SS-23 in preparing medicines for preventing and / or treating atherosclerosis, and belongs to the technical field of chemical medicines. The compound SS-23 is a compound shown in formula I or a pharmaceutically acceptable salt thereof. The phenolic acid glyceride compound SS-23 is obtained by separation and purification from Sparganium stoloniferum Buch. The compound can play a role in preventing and / or treating atherosclerosis by regulating blood lipid levels, reducing plaque area and improving blood vessel function. The compound SS-23 has significant potential in preventing and / or treating atherosclerosis, provides a new treatment strategy for clinic, and has a good application prospect. Formula I.

The present invention provides synthetic compounds having magical biological activity, compositions comprising them, processes for their preparation and their use in the treatment of diseases, symptoms and conditions.

The invention provides an ophthalmic preparation and application thereof in slowing down myopia progression, the ophthalmic preparation is brimonidine, and it is found and proved for the first time that intravitreal injection of brimonidine can delay growth of an ocular axis so as to effectively slow down the myopia progression. Due to the fact that brimonidine is injected into the vitreous cavity, growth of an ocular axis can be delayed, and the diopter of eyeballs is improved. Meanwhile, under the action of the medicine, the intraocular pressure is also remarkably reduced. The ophthalmic preparation can effectively slow down the progression of myopia, has a potential effect of delaying the progression of the aging eye course, and has a very good clinical application prospect.

The invention discloses application of an engineered dental epithelial cell exosome, and belongs to the technical field of biomedicine. The invention discloses an application of an engineered tooth epithelial cell exosome. An engineered tooth epithelial cell comprises an engineered tooth epithelial cell line HERS-H1; the application comprises the application in preparation of medicines for preventing or / and treating osteoporosis. The medicine for preventing or / and treating osteoporosis disclosed by the invention comprises an exosome of an engineered tooth epithelial cell line HERS-H1. The dental epithelial cell exosome disclosed by the invention can be taken by the bone marrow mesenchymal stem cells, and the proliferation and osteogenic differentiation of the bone marrow mesenchymal stem cells are promoted; in an ovariectomized induced osteoporosis model, the dental epithelial cell exosome is injected into the caudal vein, so that bone loss can be effectively reduced, the bone microstructure quality can be improved, and the progress of osteoporosis can be delayed.

This invention belongs to the field of biomedical technology and discloses the application of calcium-activated chloride channel AN01 / TMEM16A in the prevention and treatment of atherosclerosis. This invention also discloses the application of ANO1 promoters in the preparation of drugs for the treatment or prevention of atherosclerosis. Through research, this invention has found that the loss of ANO1 in vascular smooth muscle cells exacerbates the instability of atherosclerotic plaques, while overexpression of ANO1 can enhance the stability of atherosclerotic plaques and delay the progression of atherosclerosis. ANO1 in smooth muscle cells is one of the key drivers of atherosclerosis progression. This invention clarifies that targeting the non-ion channel function of ANO1 protein has important clinical translational value for screening drugs for the treatment or prevention of atherosclerosis.

The utility model belongs to the medical auxiliary device technical field, specifically is a kind of spine orthosis, including fixed base;The fixed base top side wall is fixed with first fixed plate;The first fixed plate top side wall is equipped with orthopedic plate;The fixed base top side wall is fixed with second fixed plate;The second fixed plate top side wall is equipped with limit stop;By setting orthopedic plate, second fixed plate, limit stop, telescopic link and movable ball block can adjust the radian of orthopedic plate, so that orthopedic plate can adapt to the spinal column form of different patients, to more effectively correct scoliosis, humpback etc. Bad body posture, and adjustable radian design, make orthopedic plate can adapt to the spinal column form and bending degree of different patients, provide more personalized correction scheme, help to slow down the progress of spinal deformity, ensure the maximization of correction effect, reduce unnecessary discomfort or stress, and provide stability and support in subsequent treatment.

Disclosed are compounds of Formula (I): (I), or a stereoisomer, tautomer or salt thereof, wherein R is as defined herein. Also disclosed are methods of using such compounds to reduce the levels of an Ikaros protein, a Helios protein, an Ailos protein, and an Eos protein; and pharmaceutical compositions comprising such compounds. These compounds are useful for the treatment of viral infections and proliferative disorders, such as cancer. (I)